A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as Add-on Therapy in Adult Subjects With Epilepsy Consisting of Uncontrolled Partial-Onset Seizures
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2017
At a glance
- Drugs Ganaxolone (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors Marinus Pharmaceuticals
- 23 Feb 2017 Results assessing safety and efficacy of a new formulation of ganaxolone, published in the Epilepsia.
- 07 Dec 2015 According to a Marinus Pharmaceuticals media release, additional responder analysis data was presented at the 69th Annual Meeting of the American Epilepsy Society.
- 07 Dec 2015 Additional responder analysis data was published in a Marinus Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History